Novocure® – Tumor Treating Fields
Pritesh Shah, Chief Commercial Officer of device maker Novocure® discusses Tumor Treating Fields, a cap-like device that aims electric fields at cancer cells to disrupt cell division and inhibit tumor growth. He describes how Tumor Treating Fields pinpoints aggressive tumors with minimal damage to healthy cells. He talks about research on possible future indications such as combining Tumor Treating Fields with Merck’s immunotherapy Keytruda® to treat non-small cell lung cancer.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Cancer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Key Takeaways
- Key Point: Pritesh Shah, Chief Commercial Officer of device maker Novocure® discusses Tumor Treating Fields, a cap-like device that aims electric fields at cancer cells to disrupt cell di…
- Key Point: Pritesh Shah joined Novocure in November 2012 and serves as Chief Commercial Officer.
- Key Point: Shah had extensive experiences in leading oncology commercial and medical affairs functions at Roche, Genentech, Bristol-Myers Squibb, OSI Oncology and AVEO Oncology.
- Key Point: He holds a Doctor of Pharmacy from the University of Maryland and a master’s degree in Strategic Communication and Leadership from Seton Hall University.
- Key Point: Health Professional Radio · Novocure® – Tumor Treating Fields
Pritesh Shah joined Novocure in November 2012 and serves as Chief Commercial Officer. Prior to joining Novocure, Mr. Shah had extensive experiences in leading oncology commercial and medical affairs functions at Roche, Genentech, Bristol-Myers Squibb, OSI Oncology and AVEO Oncology. He holds a Doctor of Pharmacy from the University of Maryland and a master’s degree in Strategic Communication and Leadership from Seton Hall University.
Health Professional Radio · Novocure® – Tumor Treating Fields
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.



